Affinity Asset Advisors, LLC Nuvalent, Inc. Transaction History
Affinity Asset Advisors, LLC
- $579 Million
- Q3 2024
A detailed history of Affinity Asset Advisors, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 337,500 shares of NUVL stock, worth $29.5 Million. This represents 5.97% of its overall portfolio holdings.
Number of Shares
337,500
Previous 200,000
68.75%
Holding current value
$29.5 Million
Previous $15.2 Million
127.56%
% of portfolio
5.97%
Previous 2.06%
Shares
5 transactions
Others Institutions Holding NUVL
# of Institutions
210Shares Held
59.5MCall Options Held
450KPut Options Held
619K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.75 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$437 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$361 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$264 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$260 Million7.96% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.76B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...